EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients

Stefania Crucitta iD, Paola Cinacchi, Irene Bargagna, Pamela Biondani, Elena Giontella, Michela Palleschi, Claudia Omarini, Lorenzo Belluzzi, Lucia Angelini, Icro Meattini, Luca Visani, Stefania Stucci und 6 weitere

Therapeutic Advances in Drug Safety · 2026-04 · 17

DOI: 10.1177/20420986251414591 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Drug Safety, online erschienen am 22.04.2026. Verfasst von Stefania Crucitta und 17 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib have rapidly become an established oral treatment for patients with ER+, HER2− locally advanced or metastatic breast cancer. The use of the oral route offers convenience and flexibility to the patient; however, the co-administration of proton pump inhibitors (PPIs) to mitigate gastrointestinal adverse events induced by anticancer treatments may decrease drug solubility, bioavailability, and potentially impact treatment efficacy.

Objectives

The present study was aimed at investigating whether PPIs may affect the progression-free survival (PFS) of patients treated with abemaciclib.

Design

Multicenter observational cohort study on clinical data collected retrospectively.

Methods

Patients with ER-positive/HER2-negative mBC candidates for a first-line treatment with abemaciclib as per clinical practice were enrolled. Patients were classified as “no concomitant PPIs” or “concomitant PPIs” if PPI administration covered not less than 2/3 of the treatment period with abemaciclib. All clinical interventions were made according to clinical practice.

Results

One hundred eight patients were enrolled in this study; 66 belonged to the “no concomitant PPIs” group and 42 to the “concomitant PPIs” group. No statistically significant difference in PFS was found between the two groups ( p = 0.77). Likewise, no difference in PFS was observed in endocrine-sensitive or -resistant mBC in the presence or absence of concomitant PPI treatment. No correlation with adverse events, including hematological or gastrointestinal toxicities, was found.

Conclusion

This study demonstrates that the administration of PPIs to patients treated with abemaciclib is not associated with clinically significant drug–drug interactions on PFS.

Schlagwörter

Stichwörter der Autor:innen

abemaciclibbreast cancerdrug–drug interactionsprogression-free survivalproton pump inhibitors

Autor:innen und Institutionen

  • Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Section of Oncology, Department of Medicine, University of Verona and University and Hospital Trust of Verona, Verona, Italy.
  • Department of Experimental Medicine, University of Salento, Lecce, Italy.
  • Division of Medical Oncology, University of Modena and Reggio Emilia, Modena, Italy.
  • Department of Experimental and Clinical Biomedical Sciences "M. Serio," University of Florence, Florence, Italy.

ORCID-Profile: Stefania Crucitta, Romano Danesi, Marzia Del Re

Zitieren

APA

Crucitta, S., Cinacchi, P., Bargagna, I., Biondani, P., Giontella, E., Palleschi, M., Omarini, C., Belluzzi, L., Angelini, L., Meattini, I., Visani, L., Stucci, S., Porta, C., Fontana, A., De Giorgi, U., Fogli, S., Danesi, R., & Del Re, M. (2026). The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients. Therapeutic Advances in Drug Safety, 17. https://doi.org/10.1177/20420986251414591

Vancouver

Crucitta S, Cinacchi P, Bargagna I, Biondani P, Giontella E, Palleschi M, et al. The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients. Therapeutic Advances in Drug Safety. 2026;17. doi:10.1177/20420986251414591

BibTeX
@article{Crucitta2026,
  author = {Crucitta, Stefania and Cinacchi, Paola and Bargagna, Irene and Biondani, Pamela and Giontella, Elena and Palleschi, Michela and Omarini, Claudia and Belluzzi, Lorenzo and Angelini, Lucia and Meattini, Icro and Visani, Luca and Stucci, Stefania and Porta, Camillo and Fontana, Andrea and De Giorgi, Ugo and Fogli, Stefano and Danesi, Romano and Del Re, Marzia},
  title = {The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients},
  journal = {Therapeutic Advances in Drug Safety},
  year = {2026},
  volume = {17},
  doi = {10.1177/20420986251414591}
}
Kostenlos starten →